Johnson & Johnson: The Rival That Already Sells the InstrumentsNarrow moat

Intuitive Surgical (ISRG) — moat facet

Intuitive spent a decade moving onto Ethicon's ground, and Ethicon's owner has now moved onto Intuitive's.

Johnson & Johnson received FDA De Novo authorisation for its Ottava robotic system on 22 July 2026, six months after filing, for a set of general-surgery procedures in the upper abdomen including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy and hiatal hernia repair1. Its architecture is genuinely different: the robot is integrated into the operating table rather than mounted on carts or booms, which J&J says takes 30% to 50% less space.

Ottava, authorised July 20266 monthsfrom submission to De Novo30-50%less operating-roomspace, J&J saysEthiconthe instrument businessJ&J already ownsFour arms integrated into the operating table rather than mounted on carts or booms.
The machine is not the competitive point. Intuitive spent a decade moving onto Ethicon's ground; Ethicon's owner has now moved onto Intuitive's.

The competitive significance is not the machine. It is that Johnson & Johnson, through Ethicon, has sold surgical staplers, energy devices and sutures into every operating room in the developed world for decades — and Intuitive has spent the past ten years moving onto exactly that ground.

Intuitive's own 10-K makes the connection explicitly: "as we add new robotically controlled products (e.g., da Vinci stapling and da Vinci energy products) that compete with product offerings traditionally within the domains of open surgery and/or conventional MIS, we face greater competition from larger and well-established companies, such as Johnson & Johnson and Medtronic plc"2. The SureForm and EndoWrist staplers, the Vessel Sealer Extend, SynchroSeal and the E-200 generator3 are all products that displace something Ethicon used to sell.

So this is not a challenger entering a market; it is a supplier of the same operating room deciding to defend it by owning the platform rather than the instrument. And the indications Ottava was cleared for are, almost item for item, the general-surgery categories driving Intuitive's recent growth.

The selected indication list is the thing to watch rather than the placements. Ottava was authorised for cholecystectomy and hiatal hernia repair on day one — two of the four procedures Intuitive named as the largest contributors to United States general surgery growth in 20254.

Moat trajectory: Narrowing

Ottava's De Novo in July 2026 puts the owner of Ethicon — the company whose laparoscopic instrument business Intuitive spent a decade taking share from — onto Intuitive's own ground, with the surgical sales force already in the building.

The number that tests this moat
Reported
U.S. general surgery procedures
About 1,250,000 in 2025, up 18%

Ottava is authorised for general surgery, Intuitive's largest U.S. category. Growth here slowing faster than elsewhere once Ottava ships would show J&J's sales force converting its instrument customers.

Source: Intuitive Surgical Form 10-K, FY2025 ↗
References
  1. ReportedJohnson & Johnson received FDA De Novo authorisation for its Ottava robotic system on 22 July 2026, six months after filing, for a set of general-surgery procedures in the upper abdomen including Roux-en-Y gastric bypass, gastrectomy,...
    MedTech Dive, 'J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive' - De Novo authorization for multiple general-surgery procedures granted about six months after submission, on a system with four arms integrated into the operating table — July 2026 · publ. July 22, 2026 · source ↗
  2. ReportedIntuitive's own 10-K makes the connection explicitly: "as we add new robotically controlled products (e.g., da Vinci stapling and da Vinci energy products) that compete with product offerings traditionally within the domains of open...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedThe SureForm and EndoWrist staplers, the Vessel Sealer Extend, SynchroSeal and the E-200 generator are all products that displace something Ethicon used to sell.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  4. ReportedOttava was authorised for cholecystectomy and hiatal hernia repair on day one — two of the four procedures Intuitive named as the largest contributors to United States general surgery growth in 2025.
    MedTech Dive, 'J&J gets FDA authorization for Ottava robot, teeing up competition with Intuitive' - De Novo authorization for multiple general-surgery procedures granted about six months after submission, on a system with four arms integrated into the operating table — July 2026 · publ. July 22, 2026 · source ↗
Sources
Generated September 23, 2026